Invetech helps cell and gene therapy developers to visualize, strategize and manage the future. With proven processes, expert insights and full-spectrum services, we swiftly accelerate life-changing therapies from clinical to commercial-scale manufacturing. With configurable technology platforms and automated production systems, we enable predictable, reproducible products of the highest quality and efficacy. Our integrated approach brings together biological scientists, engineers, designers and program managers to deliver successful market offerings to more people globally. Working in close collaboration with early-stage and mature life science companies, we are committed to advancing the next generation of vital, emerging therapies to revolutionize healthcare and precision medicine.
One of the continued challenges for scalable commercial manufacturing of cell therapies is closing and automating the entire manufacturing process. Many core manufacturing processes may be closed, but peripheral systems e.g. media formulation, viral vector packaging remain open – introducing opportunities for failures.
Invetech’s approach enables manufacturers to close and integrate both core and peripheral processes.
Our in-depth understanding of platforms and processes support seamless configuration and integration of equipment with single-use systems tailored for specific manufacturing needs. This complete life-cycle approach assures compatibility and quality at every stage – giving you more certainty in the outcome. All elements are robust, GMP compliant, closed, cleanable and validatable.
Our novel systems include:
- Formulation and fill of bulk media preparations and viral vectors
- Formulation and filling of cell products
- Preparation of blood products/starting materials for applications such as leukaphoresis
- Washing and harvesting cell suspensions
All these systems have been qualified and deployed in GMP manufacturing environments.
Panelists from Lonza, Takeda and Vor Biopharma share their insights on how to best introduce disruptive technologies into cell therapy manufacturing processes.
In this webinar, industry experts share common and uncommon challenges encountered when closing and automating ancillary processes, and how improved scalability and reproducibility were achieved by moving to closed automated platforms.
One of the continued challenges for scalable commercial manufacturing of cell therapies is closing and automating the entire manufacturing process. Many core manufacturing processes may be closed, but peripheral systems e.g. media formulation, viral vector packaging remain open – introducing opportunities for failures. Invetech’s approach enables manufacturers to close and integrate both core and peripheral processes.
The high cost of producing new cell and gene therapies is one of the largest issues facing the industry. After launching Kymriah and Yescarta, Novartis’ price tags were $475,000 and $375,000, respectively. Advancements in manufacturing are driving costs down, but not at the required pace.
3rd Generation Filling System is an automated bag filling platform for GMP manufacturing.
Solving commercial manufacturing challenges in cell and gene therapy.
Invetech's 3rd generation filling system is an automated bag filling platform for GMP manufacturing. Watch this video to see a glimpse of the core capabilities of this system.
A recent panel discussion hosted by Invetech during the recent International Society Cell & Gene Therapy (ISCT) conference in Melbourne, Australia explores the main challenges along the pathway from process development to commercial cell therapies.
The commercial success of a cell-based therapeutic depends on a scalable, automated manufacturing process. But how can companies ensure their manufacturing processes are up to meeting the needs and market demand of the rapidly evolving cell therapy field? Our annual breakfast briefing at the Phacilitate Leaders World conference 2020 in Miami tackled this and other current topics.